Gentile Pietro
Department of Surgical Science, "Tor Vergata" University, 00133 Rome, Italy.
Academy of International Regenerative Medicine & Surgery Societies (AIRMESS), 1201 Geneva, Switzerland.
Biomedicines. 2022 May 19;10(5):1179. doi: 10.3390/biomedicines10051179.
The potential role of mesenchymal stem cells (MSCs) in the treatment of metastatic cancers, including breast cancer, has been investigated for many years leading to encouraging results. The role of fat grafting and the related adipose-derived mesenchymal stem cells (AD-MSCs) has been detailed and described for breast reconstruction purposes confirming the safety of AD-MSCs. MSCs have great potential for delivering anticancer agents, suicide genes, and oncolytic viruses to tumors. Currently, many studies have focused on the products of MSCs, including extracellular vesicles (EVs), as a cell-free therapy. This work aimed to review and discuss the current knowledge on MSCs and their EVs in breast cancer therapy.
间充质干细胞(MSCs)在包括乳腺癌在内的转移性癌症治疗中的潜在作用已被研究多年,并取得了令人鼓舞的结果。脂肪移植及相关脂肪来源的间充质干细胞(AD-MSCs)在乳房重建中的作用已得到详细描述,证实了AD-MSCs的安全性。MSCs在向肿瘤递送抗癌药物、自杀基因和溶瘤病毒方面具有巨大潜力。目前,许多研究聚焦于MSCs的产物,包括细胞外囊泡(EVs),将其作为一种无细胞疗法。这项工作旨在回顾和讨论目前关于MSCs及其EVs在乳腺癌治疗中的知识。